Correlation Engine 2.0
Clear Search sequence regions


  • 2 di‐ n‐ propylamino)‐ tetralin (1)
  • 4 and (1)
  • 5 HT (24)
  • 5 HT receptors (2)
  • 5 HT1A (13)
  • 5 ht1a agonists (6)
  • 5 ht1a antagonist (2)
  • 5 HT1A receptors (27)
  • 5HT1A (1)
  • 6 ohda (129)
  • 8 oh (30)
  • 8 oh‐ dpat (32)
  • abdomen (1)
  • acid (3)
  • AE 2 (1)
  • agonists 5‐ ht (2)
  • amino acid (9)
  • anaesthesia (2)
  • analysis data (3)
  • anti‐ igg (3)
  • AP 4 (3)
  • axial (6)
  • basal ganglia (5)
  • brain (8)
  • california (2)
  • cases (3)
  • conflict (2)
  • contains (1)
  • D3 receptor (1)
  • data file (5)
  • design experiments (2)
  • diaminobenzidine (2)
  • disease and (4)
  • dopamine (27)
  • drug dose (1)
  • drugs treatments (2)
  • dura mater (1)
  • dyskinesia (21)
  • effect drugs (7)
  • effect gaba (1)
  • electrodes (1)
  • ethanol (1)
  • fast (1)
  • fibres (1)
  • fiji (2)
  • focuses (1)
  • forelimb (8)
  • fourier transform (1)
  • gaba (21)
  • gelatin (1)
  • globus pallidus (3)
  • hamilton (1)
  • help (1)
  • hplc (2)
  • HT1A 1 (1)
  • ice (2)
  • interneurons (1)
  • japan (2)
  • jugular vein (1)
  • l dopa receptor (1)
  • l- dopa (102)
  • ligands (2)
  • limb (6)
  • measures (8)
  • medial forebrain bundle (3)
  • mercaptoethanol (1)
  • methanol (3)
  • methyl (1)
  • mgcl2 (2)
  • mice (1)
  • microdialysis (16)
  • modulates gaba (1)
  • motor cortex (3)
  • motor symptoms (4)
  • movements (20)
  • netherlands (1)
  • neurons (61)
  • NMDA receptor (1)
  • parkinson disease (20)
  • pars (120)
  • patient (5)
  • period (5)
  • phase (1)
  • phosphate (3)
  • picric acid (1)
  • potassium (1)
  • problem (1)
  • protein targets (1)
  • proteins humans (1)
  • protocols (2)
  • rats (60)
  • reagent (1)
  • receptor (4)
  • receptors 5‐ ht (1)
  • receptors 5‐ ht1a (1)
  • research (2)
  • rigour (2)
  • SERT (19)
  • serum (1)
  • sex (2)
  • sex‐ differences (1)
  • sham (41)
  • signal (10)
  • slides (2)
  • sodium (1)
  • sodium acetate (1)
  • solutions (1)
  • spain (2)
  • student (1)
  • substantia nigra (121)
  • target drugs (3)
  • targets protein (1)
  • tetrahydrofuran (1)
  • thus acid (1)
  • tokyo (2)
  • toxin (1)
  • treatment effect (1)
  • tremors (1)
  • triton x‐ 100 (2)
  • trizma (1)
  • under anaesthesia (1)
  • weight (1)
  • Sizes of these terms reflect their relevance to your search.

    l-DOPA-induced dyskinesia (LID) is considered a major complication in the treatment of Parkinson's disease (PD). Buspirone (5-HT1A partial agonist) have shown promising results in the treatment of PD and LID, however no 5-HT-based treatment has been approved in PD. The present study was aimed to investigate how the substantia nigra pars reticulata (SNr) is affected by buspirone and whether it is a good target to study 5-HT antidyskinetic treatments. Buspirone was studied using in vivo single-unit, electrocorticogram, local field potential recordings along with microdialysis and immunohistochemistry in naïve/sham, 6-hydroxydopamine (6-OHDA)-lesioned or 6-OHDA-lesioned and l-DOPA-treated (6-OHDA/l-DOPA) rats. Local buspirone inhibited SNr neuron activity in all groups. However, systemic buspirone reduced burst activity in 6-OHDA-lesioned rats (with or without l-DOPA treatment), whereas 8-OH-DPAT, a full 5-HT1A agonist induced larger inhibitory effects in sham animals. Neither buspirone nor 8-OH-DPAT markedly modified the low-frequency oscillatory activity in the SNr or synchronization within the SNr with the cortex. In addition, local perfusion of buspirone increased GABA and glutamate release in the SNr of naïve and 6-OHDA-lesioned rats but no effect in 6-OHDA/l-DOPA rats. In the 6-OHDA/l-DOPA group, increased 5-HT transporter and decreased 5-HT1A receptor expression was found. The effects of buspirone in SNr are influenced by dopamine loss and l-DOPA treatment. The present results suggest that the regulation of burst activity of the SNr induced by DA loss may be a good target to test new drugs for the treatment of PD and LID. © 2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

    Citation

    Sergio Vegas-Suárez, Clarissa Anna Pisanò, Catalina Requejo, Harkaitz Bengoetxea, Jose Vicente Lafuente, Michele Morari, Cristina Miguelez, Luisa Ugedo. 6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata. British journal of pharmacology. 2020 Jul 06;177(17):3957-3974


    PMID: 32464686

    View Full Text